(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Abivax Sa's revenue in 2025 is N/A.On average, 3 Wall Street analysts forecast ABVX's revenue for 2025 to be $508,301,273, with the lowest ABVX revenue forecast at $342,461,245, and the highest ABVX revenue forecast at $805,227,856. On average, 2 Wall Street analysts forecast ABVX's revenue for 2026 to be $513,691,867, with the lowest ABVX revenue forecast at $342,461,245, and the highest ABVX revenue forecast at $684,922,489.
In 2027, ABVX is forecast to generate $4,131,794,916 in revenue, with the lowest revenue forecast at $713,080,414 and the highest revenue forecast at $7,507,511,507.